NCT01163799 - A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

August 31, 2012

Conditions

Transplant; Failure, Kidney

Interventions

DRUG

Alefacept (ASP0485)

Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.

Trial Locations (1)

60611

Northwestern Memorial Hospital, Chicago